MISSION Therapeutics

About:

MISSION Therapeutics develops therapies that enhance the removal of dysfunctional mitochondria to combat serious diseases.

Website: http://www.missiontherapeutics.com

Twitter/X: MISSIONTherapeu

Top Investors: Innovate UK, IP Group, SR One, Sofinnova Partners, Michael J. Fox Foundation

Description:

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Total Funding Amount:

$180M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Cambridge, Cambridgeshire, United Kingdom

Founded Date:

2011-01-01

Contact Email:

info(AT)missiontherapeutics.com

Founders:

Niall Martin, Steve Jackson, Xavier Jacq

Number of Employees:

51-100

Last Funding Date:

2024-07-02

IPO Status:

Private

Industries:

© 2025 bioDAO.ai